The Uses and Abuses of Vitamin D Compounds in Chronic Kidney Disease–Mineral Bone Disease (CKD–MBD)

Ortiz, 2014, Epidemiology, contributors to, and clinical trials of mortality risk in chronic kidney failure, Lancet, 383, 1831, 10.1016/S0140-6736(14)60384-6 Lindner, 1974, Accelerated atherosclerosis in prolonged maintenance hemodialysis, N Engl J Med, 290, 697, 10.1056/NEJM197403282901301 Neovius, 2014, Mortality in chronic kidney disease and renal replacement therapy: a population-based cohort study, BMJ Open, 4, e004251, 10.1136/bmjopen-2013-004251 Hajhosseiny, 2013, Cardiovascular disease in chronic kidney disease: untying the Gordian knot, Int J Clin Pract, 67, 14, 10.1111/j.1742-1241.2012.02954.x Cozzolino, 2014, on Behalf of the CKD-MBD Working Group of ERA-EDTA. Is chronic kidney disease-mineral bone disorder (CKD-MBD) really a syndrome?, Nephrol Dial Transplant, 29, 1815, 10.1093/ndt/gft514 Goldsmith, 2011, Mineral metabolism and vitamin D in chronic kidney disease--more questions than answers, Nat Rev Nephrol, 7, 341, 10.1038/nrneph.2011.53 Leckstroem, 2014, The trials and tribulations of vitamin D: time for the ‘sunshine’ vitamin to come in out of the cold – or just more broken promises?, Expert Rev Endocrinol Metab, 1, 1 Cunningham, 2011, Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options, Clin J Am Soc Nephrol, 6, 913, 10.2215/CJN.06040710 Martin, 2004, Diagnosis, assessment, and treatment of bone turnover abnormalities in renal osteodystrophy, Am J Kidney Dis, 43, 558, 10.1053/j.ajkd.2003.12.003 Vervloet, 2014, Bone: a new endocrine organ at the heart of chronic kidney disease and mineral and bone disorders, Lancet Diabetes Endocrinol, 2, 427, 10.1016/S2213-8587(14)70059-2 Ensrud, 2013, Fracture risk in CKD, Clin J Am Soc Nephrol, 8, 1282, 10.2215/CJN.06300613 Elliott, 2013, Estimated GFR and fracture risk: a population-based study, Clin J Am Soc Nephrol, 8, 1367, 10.2215/CJN.09130912 Nair, 2013, Temporal trends in the incidence, treatment, and outcomes of hip fracture in older patients initiating dialysis in the United States, Clin J Am Soc Nephrol, 8, 1336, 10.2215/CJN.10901012 Gutierrez, 2010, Fibroblast growth factor 23 and disordered vitamin D metabolism in chronic kidney disease: updating the "trade-off" hypothesis, Clin J Am Soc Nephrol, 5, 1710, 10.2215/CJN.02640310 Galitzer, 2010, Parathyroid cell resistance to fibroblast growth factor 23 in secondary hyperparathyroidism of chronic kidney disease, Kidney Int, 77, 211, 10.1038/ki.2009.464 Mawer, 1973, Failure of formation of 1,25-dihydroxycholecalciferol in chronic renal insufficiency, Lancet, 1, 626, 10.1016/S0140-6736(73)92197-1 Ishimura, 1999, Serum levels of 1,25-dihydroxyvitamin D, 24,25-dihydroxyvitamin D, and 25-hydroxyvitamin D in nondialyzed patients with chronic renal failure, Kidney Int, 55, 1019, 10.1046/j.1523-1755.1999.0550031019.x Kawashima, 1982, Metabolic acidosis suppresses 25-hydroxyvitamin in D3-1alpha-hydroxylase in the rat kidney. Distinct site and mechanism of action, J Clin Invest, 70, 135, 10.1172/JCI110586 Gutierrez, 2005, Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease, J Am Soc Nephrol, 16, 2205, 10.1681/ASN.2005010052 Garrett, 2013, PTH - a particularly tricky hormone: why measure it at all in kidney patients?, Clin J Am Soc Nephrol, 8, 299, 10.2215/CJN.09580911 Stanbury, 1957, Azotaemic renal osteodystrophy, Br Med Bull, 13, 57, 10.1093/oxfordjournals.bmb.a069572 Fournier, 1979, Comparison of 1 alpha-hydroxycholecalciferol and 25-hydroxycholecalciferol in the treatment of renal osteodystrophy: greater effect of 25-hydroxycholecalciferol on bone mineralization, Kidney Int, 15, 196, 10.1038/ki.1979.25 Hamdy, 1995, Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure, BMJ, 310, 358, 10.1136/bmj.310.6976.358 Baker, 1986, Controlled trial of calcitriol in hemodialysis patients, Clin Nephrol, 26, 185 Palmer, 2009, Vitamin D compounds for people with chronic kidney disease requiring dialysis, Cochrane Database Syst Rev, 4 Palmer, 2007, Meta-analysis: vitamin D compounds in chronic kidney disease, Ann Intern Med, 147, 840, 10.7326/0003-4819-147-12-200712180-00004 Moorthi, 2011, Optimal vitamin D, calcitriol, and vitamin D analogue replacement in chronic kidney disease: to D or not to D: that is the question, Curr Opin Nephrol Hypertens, 20, 354, 10.1097/MNH.0b013e3283470450 Kandula, 2011, Vitamin D supplementation in chronic kidney disease: a systematic review and meta-analysis of observational studies and randomized controlled trials, Clin J Am Soc Nephrol, 6, 50, 10.2215/CJN.03940510 Liabeuf, 2014, Vascular calcification in chronic kidney disease: are biomarkers useful for probing the pathobiology and the health risks of this process in the clinical scenario?, Nephrol Dial Transplant, 29, 1275, 10.1093/ndt/gft368 Leonard, 2013, Regression of vascular calcification in chronic kidney disease - feasible or fantasy? a review of the clinical evidence, Br J Clin Pharmacol, 76, 560 Donate-Correa, 2014, Beneficial effects of selective vitamin D receptor activation by paricalcitol in chronic kidney disease, Curr Drug Targets, 15, 703, 10.2174/1389450115666140417120902 Somjen, 2014, New vitamin D less-calcemic analog affect human bone cell line and cultured vascular smooth muscle cells similar to other less-calcemic analogs, J Steroid Biochem Mol Biol, 140, 1, 10.1016/j.jsbmb.2013.11.007 Martínez-Moreno, 2012, In vascular smooth muscle cells paricalcitol prevents phosphate-induced Wnt/β-catenin activation, Am J Physiol Renal Physiol, 303, F1136, 10.1152/ajprenal.00684.2011 Cozzolino, 2012, Vitamin D receptor activation and prevention of arterial ageing, Nutr Metab Cardiovasc Dis, 22, 547, 10.1016/j.numecd.2012.03.010 Covic, 2010, The effects of vitamin D therapy on left ventricular structure and function - are these the underlying explanations for improved CKD patient survival?, Nephron Clin Pract, 116, c187, 10.1159/000317198 Panizo, 2013, Vitamin D receptor activation, left ventricular hypertrophy and myocardial fibrosis, Nephrol Dial Transplant, 28, 2735, 10.1093/ndt/gft268 Lund, 2010, Differential effects of paricalcitol and calcitriol on intestinal calcium absorption in hemodialysis patients, Am J Nephrol, 31, 165, 10.1159/000266204 Tentori, 2006, Medical Directors of Dialysis Clinic Inc. Mortality risk among hemodialysis patients receiving different vitamin D analogs, Kidney Int, 70, 1858, 10.1038/sj.ki.5001868 Sprague, 2003, Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism, Kidney Int, 63, 1483, 10.1046/j.1523-1755.2003.00878.x Suh, 2013, Anti-apoptotic effect of paricalcitol in gentamicin-induced kidney injury, Korean J Physiol Pharmacol, 17, 435, 10.4196/kjpp.2013.17.5.435 Park, 2010, Renoprotective effects of paricalcitol on gentamicin-induced kidney injury in rats, Am J Physiol Renal Physiol, 298, F301, 10.1152/ajprenal.00471.2009 Meems, 2012, The vitamin D receptor activator paricalcitol prevents fibrosis and diastolic dysfunction in a murine model of pressure overload, J Steroid Biochem Mol Biol, 132, 282, 10.1016/j.jsbmb.2012.06.004 Finch, 2012, Effect of combining an ACE inhibitor and a VDR activator on glomerulosclerosis, proteinuria, and renal oxidative stress in uremic rats, Am J Physiol Renal Physiol, 302, F141, 10.1152/ajprenal.00293.2011 Sanchez-Niño, 2012, Beyond proteinuria: VDR activation reduces renal inflammation in experimental diabetic nephropathy, Am J Physiol Renal Physiol, 302, F647, 10.1152/ajprenal.00090.2011 Kong, 2010, Therapeutic effects of vitamin D analogues on cardiac hypertrophy in spontaneously hypertensive rats, Am J Pathol, 177, 622, 10.2353/ajpath.2010.091292 Husain, 2009, Combination therapy with paricalcitol and enalapril ameliorates cardiac oxidative injury in uremic rats, Am J Nephrol, 29, 465, 10.1159/000178251 Mizobuchi, 2007, Differential effects of vitamin D receptor activators on vascular calcification in uremic rats, Kidney Int, 72, 709, 10.1038/sj.ki.5002406 Mizobuchi, 2010, Myocardial effects of VDR activators in renal failure, J Steroid Biochem Mol Biol, 121, 188, 10.1016/j.jsbmb.2010.03.026 Cardús, 2007, Differential effects of vitamin D analogs on vascular calcification, J Bone Miner Res, 22, 860, 10.1359/jbmr.070305 Zheng, 2013, Vitamin D supplementation and mortality risk in chronic kidney disease: a meta-analysis of 20 observational studies, BMC Nephrol, 14, 199, 10.1186/1471-2369-14-199 Miller, 2012, Administered paricalcitol dose and survival in hemodialysis patients: a marginal structural model analysis, Pharmacoepidemiol Drug Saf, 21, 1232, 10.1002/pds.3349 Hansen, 2012, A randomised clinical study of alfacalcidol and paricalcitol, Dan Med J, 59, B4400 Cheng, 2012, Efficacy and safety of paricalcitol therapy for chronic kidney disease: a meta-analysis, Clin J Am Soc Nephrol, 7, 391, 10.2215/CJN.03000311 Hansen, 2009, Treatment of secondary hyperparathyroidism in haemodialysis patients: a randomised clinical trial comparing paricalcitol and alfacalcidol, BMC Nephrol, 10, 28, 10.1186/1471-2369-10-28 Kalantar-Zadeh, 2007, Survival differences between activated injectable vitamin D2 and D3 analogs, Kidney Int, 71, 827, 10.1038/sj.ki.5002208 de Zeeuw, 2010, Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial, Lancet, 376, 1543, 10.1016/S0140-6736(10)61032-X de Borst, 2013, Active vitamin D treatment for reduction of residual proteinuria: a systematic review, J Am Soc Nephrol, 24, 1863, 10.1681/ASN.2013030203 Tamez, 2012, Vitamin D reduces left atrial volume in patients with left ventricular hypertrophy and chronic kidney disease, Am Heart J, 164, 902, 10.1016/j.ahj.2012.09.018 Thadhani, 2012, Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial, JAMA, 307, 674, 10.1001/jama.2012.120 Wang, 2014, Effect of paricalcitol on left ventricular mass and function in CKD—the OPERA trial, J Am Soc Nephrol, 25, 175, 10.1681/ASN.2013010103